title: Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
abstract: Trimetrexate glucuronate in combination therapy with cisplatin or etoposide was evaluated in non-small cell lung cancer patients in a pilot, dose escalation study. Trimetrexate was administered intravenously together with 20 mg/m2 cisplatin or 50 mg/m2 etoposide for 5 consecutive days at an initial dose of 4 mg/m2. Courses were repeated at 3 week intervals with the trimetrexate dosage escalated according to patient tolerance. In the 12 patients treated to date, reversible myelosuppression, consisting of leukopenia and thrombocytopenia, and nonhematologic grade 1 and 2 toxicities were observed. The study is ongoing. The maximum tolerated trimetrexate dosage levels in combination therapy will be established.
authors.affiliation: Ottawa General Hospital, Ontario, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Maroun
authors.forename: R B
authors.initials: RB
authors.lastname: Natale
authors.forename: F
authors.initials: F
authors.lastname: Robert
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000008:administration & dosage*; D016597:Trimetrexate
chemical_list: D011799:Quinazolines; D005047:Etoposide; D002945:Cisplatin; D016597:Trimetrexate